Phreesia, Inc. (NYSE:PHR) COO Evan Roberts Sells 3,519 Shares

Phreesia, Inc. (NYSE:PHR) COO Evan Roberts sold 3,519 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $30.06, for a total value of $105,781.14. Following the sale, the chief operating officer now owns 741,197 shares of the company’s stock, valued at approximately $22,280,381.82. This represents a 0.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Evan Roberts also recently made the following trade(s):

• On Thursday, February 13th, Evan Roberts sold 16,005 shares of Phreesia stock. The shares were sold at an average price of $30.00, for a total value of $480,150.00.
• On Monday, January 27th, Evan Roberts sold 10,716 shares of Phreesia stock. The shares were sold at an average price of $27.48, for a total value of $294,475.68.
• On Tuesday, January 21st, Evan Roberts sold 12,749 shares of Phreesia stock. The stock was sold at an average price of $27.31, for a total value of $348,175.19.
• On Wednesday, January 15th, Evan Roberts sold 1,785 shares of Phreesia stock. The stock was sold at an average price of $26.98, for a total value of $48,159.30.
• On Wednesday, January 8th, Evan Roberts sold 2,681 shares of Phreesia stock. The stock was sold at an average price of $27.95, for a total value of $74,933.95.
• On Monday, January 6th, Evan Roberts sold 2,873 shares of Phreesia stock. The stock was sold at an average price of $26.61, for a total value of $76,450.53.

Phreesia Price Performance

NYSE:PHR opened at $28.20 on Friday. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $30.53. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $1.64 billion, a PE ratio of -19.18 and a beta of 0.96. The stock’s 50-day moving average price is $27.29 and its 200-day moving average price is $23.84.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The firm had revenue of $106.80 million for the quarter, compared to analysts’ expectations of $106.33 million. During the same period last year, the firm earned ($0.58) EPS. The company’s quarterly revenue was up 16.6% on a year-over-year basis. As a group, equities analysts expect that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PHR. International Assets Investment Management LLC lifted its stake in Phreesia by 2,179.7% in the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock valued at $33,000 after buying an additional 1,395 shares in the last quarter. Arcadia Investment Management Corp MI lifted its stake in Phreesia by 9.5% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 97,085 shares of the company’s stock valued at $2,213,000 after buying an additional 8,460 shares in the last quarter. TimesSquare Capital Management LLC lifted its stake in Phreesia by 2.3% in the 3rd quarter. TimesSquare Capital Management LLC now owns 868,409 shares of the company’s stock valued at $19,791,000 after buying an additional 19,395 shares in the last quarter. Versor Investments LP purchased a new position in Phreesia in the 3rd quarter worth approximately $694,000. Finally, GSA Capital Partners LLP lifted its stake in Phreesia by 418.3% in the 3rd quarter. GSA Capital Partners LLP now owns 49,553 shares of the company’s stock worth $1,129,000 after purchasing an additional 39,993 shares in the last quarter. 92.10% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on PHR shares. Needham & Company LLC restated a “buy” rating and issued a $29.00 target price on shares of Phreesia in a research note on Friday, January 10th. KeyCorp increased their price target on Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 8th. Citigroup increased their price target on Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Robert W. Baird cut their price target on Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $33.00 price target (up from $31.00) on shares of Phreesia in a research report on Wednesday, January 29th. Thirteen research analysts have rated the stock with a buy rating, According to MarketBeat, Phreesia currently has a consensus rating of “Buy” and an average target price of $31.15.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.